Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 16/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25828843 | 0.87 | CYP2D6 (0.46) | CYP2D6SMN1; SMN2CYP3A4ALDH1A1MAPK1 | |
| SCHEMBL22794500 | 0.85 | CYP2D6 (0.45) | CYP2D6SMN1; SMN2CYP3A4ALDH1A1MAPK1 | |
| SCHEMBL23696269 | 0.84 | CYP2D6 (0.46) | CYP2D6SMN1; SMN2CYP3A4ALDH1A1MAPK1 | |
| SCHEMBL23568519 | 0.83 | CYP2D6 (0.32) | CYP2D6TSHRPIK3CD | |
| SCHEMBL25833008 | 0.83 | EPHX1 (0.34) | — | |
| SCHEMBL23945809 | 0.81 | — | — | |
| SCHEMBL26246996 | 0.80 | HRH3 (0.32) | CYP2D6 | |
| SCHEMBL22526540 | 0.80 | CYP2D6 (0.49) | CYP2D6SMN1; SMN2CYP3A4ALDH1A1MAPK1 | |
| SCHEMBL23807297 | 0.80 | CYP2D6 (0.49) | CYP2D6SMN1; SMN2CYP3A4ALDH1A1MAPK1 | |
| SCHEMBL25725785 | 0.79 | CYP2D6 (0.43) | CYP2D6SMN1; SMN2CYP3A4ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CYP2D6 3599/4885SMN1; SMN2 2647/4885CYP3A4 2542/4885 |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | CYP2D6 474/4885SMN1; SMN2 3385/4885CYP3A4 649/4885 |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | CYP2D6 1170/4885SMN1; SMN2 3149/4885CYP3A4 1072/4885 |
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CYP2D6 3599/4885SMN1; SMN2 2647/4885CYP3A4 2542/4885 |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | CYP2D6 2910/4885SMN1; SMN2 716/4885CYP3A4 2211/4885 |
| US-11117889-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CYP2D6 3599/4885SMN1; SMN2 2647/4885CYP3A4 2542/4885 |
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | CYP2D6 698/4885SMN1; SMN2 4117/4885CYP3A4 143/4885 |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CYP2D6 3599/4885SMN1; SMN2 2647/4885CYP3A4 2542/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CYP2D6 3599/4885SMN1; SMN2 2647/4885CYP3A4 2542/4885 |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | CYP2D6 973/4885SMN1; SMN2 2737/4885CYP3A4 938/4885 |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, ITK, CRKL | CYP2D6 435/4885SMN1; SMN2 3861/4885CYP3A4 106/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CYP2D6 3599/4885SMN1; SMN2 2647/4885CYP3A4 2542/4885 |
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CYP2D6 3599/4885SMN1; SMN2 2647/4885CYP3A4 2542/4885 |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | CYP2D6 4577/4885SMN1; SMN2 832/4885CYP3A4 3981/4885 |
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CYP2D6 3599/4885SMN1; SMN2 2647/4885CYP3A4 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.